Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03689244 · ClinicalTrials.gov registry record · Phase 3
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
A Phase 3 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
NCT03689244 is a Phase 3 study that was terminated before completion, run by Actelion. The registered enrollment target is 128 participants.
The verdict
NCT03689244, a Phase 3 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
Study Summary
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other PAH medicines in CTEPH, it is believed that selexipag could benefit to patients with CTEPH. This study aims to assess the efficacy and safety of selexipag in participants with inoperable or persistent/recurrent CTEPH.
Interventions
- DRUG Placebo
- DRUG Selexipag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2022-06-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03689244
The ClinicalTrials.gov registry entry for NCT03689244 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03689244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03689244 about?
NCT03689244 is a clinical study titled "A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment". Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other PAH medicines in CTEPH, it is believed that selexipag could benefit to...
What is the current status of trial NCT03689244?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2019-01-23. Estimated completion is 2022-06-07.
What interventions are being tested in trial NCT03689244?
The interventions under investigation include: Placebo (DRUG), Selexipag (DRUG).
Who is sponsoring clinical trial NCT03689244?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.